Skip to main content
HCONRES 75 109th Congress House Foreign Trade and International Finance Access to health care Canada Commerce Consumer education Consumer protection Crime and Law Enforcement Crime prevention Deregulation Drug approvals Drug industry Drugs Economics and Public Finance Health Health care industry Health education Imports Pharmaceutical research Prescription pricing Price discrimination

Expressing the sense of the Congress that the illegal importation of prescription drugs severely undermines the regulatory protections afforded to United States consumers, and for other purposes.

Introduced: February 17, 2005 Introduced by: Meeks, Gregory W. Democratic · New York See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Mar 14, 2005
Referred to the Subcommittee on Health.
Feb 28, 2005
Referred to the Subcommittee on Health.
Feb 17, 2005
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Feb 17, 2005
Introduced in House
 Plain-English summary Congressional Research Service

Expresses the sense of Congress regarding the illegal importation of prescription drugs.

Urges the President to take action to prevent the illegal importation of prescription drugs from Canada or any other foreign country, and the U.S. Trade Representative to act to correct the inequities and discrimination caused by Canada's Patented Medicine Pricing Review Board.

Urges the pharmaceutical industry and the health care community to: (1) begin a nationwide educational awareness program for U.S. consumers regarding the dangers of imported drugs; and (2) work to ensure that all citizens have access to prescription drugs with the same level of safety and efficacy guaranteed under the current system of regulation.

Declares that: (1) it is essential that U.S. patients have access to affordable prescription drugs; and (2) deregulating foreign prices would increase the flow of new drugs to U.S. consumers.

What's happening now March 14, 2005

Referred to the Subcommittee on Health.

 Committees of jurisdiction 4